CLINICAL TRIALS PROFILE FOR EPIVIR-HBV

505(b)(2) Clinical Trials for EPIVIR-HBV

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Bristol-Myers Squibb	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Dupont Applied Biosciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.

All Clinical Trials for EPIVIR-HBV

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002168 ↗	A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients	Completed	Bristol-Myers Squibb	N/A	1969-12-31	The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.
NCT00002183 ↗	A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection	Completed	Glaxo Wellcome	Phase 1	1969-12-31	To assess the safety and tolerance of multiple oral doses of 141W94 alone, in combination with 1592U89, and in combination with Retrovir and Epivir, administered to patients with HIV infection as measured by the development of clinical adverse experiences and laboratory test abnormalities. To determine the steady-state pharmacokinetics of 141W94 alone and in combination with 1592U89 after multiple oral dosing. To obtain preliminary evidence of antiretroviral activity of 141W94 alone and in combination with 1592U89, the antiretroviral effect of combined Retrovir/Epivir and the antiretroviral effect of 141W94 when added to Retrovir/Epivir or to 1592U89/Retrovir/Epivir.
NCT00002195 ↗	A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 3	1969-12-31	The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.

Clinical Trial Conditions for EPIVIR-HBV

Condition Name

Condition Name for EPIVIR-HBV
Intervention	Trials
HIV Infections	26
HIV-1 Infection	4
HIV	4

Condition MeSH

Condition MeSH for EPIVIR-HBV
Intervention	Trials
HIV Infections	31
Acquired Immunodeficiency Syndrome	8
Infections	7

Clinical Trial Locations for EPIVIR-HBV

Trials by Country

Trials by Country for EPIVIR-HBV
Location	Trials
United States	118
India	7
Korea, Republic of	7
Spain	7
Thailand	6

Trials by US State

Trials by US State for EPIVIR-HBV
Location	Trials
New York	12
California	11
Texas	8
Illinois	7
Massachusetts	6

Clinical Trial Progress for EPIVIR-HBV

Clinical Trial Phase

Clinical Trial Phase for EPIVIR-HBV
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for EPIVIR-HBV
Clinical Trial Phase	Trials
Completed	36
Unknown status	4
Withdrawn	2

Clinical Trial Sponsors for EPIVIR-HBV

Sponsor Name

Sponsor Name for EPIVIR-HBV
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	8
Glaxo Wellcome	8
Bristol-Myers Squibb	5

Sponsor Type

Sponsor Type for EPIVIR-HBV
Sponsor	Trials
Other	37
Industry	27
NIH	17

Clinical Trials Update, Market Analysis, and Projection for Epivir-HBV

Last updated: January 27, 2026

Executive Summary

Epivir-HBV (lamivudine) is an antiviral agent primarily indicated for hepatitis B virus (HBV) infection. As a long-standing therapeutic option, the drug's clinical development, market dynamics, and future valuation hinge on evolving treatment guidelines, emerging resistance patterns, and competitive landscape shifts. This report consolidates recent clinical trial activities, provides a detailed market analysis, and offers future projections grounded in current trends.

Clinical Trials Update

Recent and Ongoing Clinical Trials

Table 1 summarizes key clinical trials involving Epivir-HBV, focusing on recent developments within the past 24 months:

Trial ID	Phase	Objective	Population	Status	Key Findings/Notes
NCT04512222	III	Evaluating efficacy of lamivudine vs tenofovir in co-infected HBV and HIV patients	Co-infected adults	Completed	Demonstrated non-inferiority in viral suppression but higher resistance with lamivudine
NCT05078923	II	Combining lamivudine with immunomodulators in resistant HBV strains	Resistant HBV	Recruiting	Early data suggest enhanced viral suppression, resistance mitigation needs further review
NCT04836576	III	Long-term safety of lamivudine in pediatric patients	Pediatric HBV	Completed	Confirmed safety profile; resistance remains concern
NCT05234534	IV (observational)	Real-world efficacy of lamivudine in resource-limited settings	Global	Ongoing	Data pending

Clinical Development Trends

• Resistance Management: Resistance development, primarily due to YMDD motif mutations, remains a challenge, prompting trials exploring combination regimens (e.g., lamivudine + tenofovir) to curb resistance.
• Pediatric Indications: Expanded trials focus on safe, long-term use in pediatric populations, given the chronicity of HBV in children.
• Treatment Duration Studies: Investigations into finite therapy duration durations, with recent findings suggesting potential for shorter courses when combined with other agents.

Regulatory and Labeling Changes

• FDA & EMA Updates: In 2021, the FDA maintained lamivudine’s approval for chronic HBV, emphasizing the importance of resistance monitoring.
• New Submissions: No major new drug applications or label updates initiated recently, reflecting a stable regulatory landscape.

Market Analysis

Market Overview & Segmentation

Segment	Details	Market Share (2022)	Key Players	Growth Drivers
Hepatitis B Treatment	Chronic HBV management	~$2.4 billion	Gilead (Epclusa), AbbVie, GlaxoSmithKline	Rising HBV prevalence, drug affordability
Drug Type	Nucleoside/nucleotide analogs	Dominates 85%	(see below)	Long-standing use, clinician familiarity
Geography	North America, Europe, Asia-Pacific	Asia-Pacific > North America	GSK, Gilead, AbbVie	High HBV endemicity in Asia

Competitive Landscape

Table 2 compares Epivir-HBV with key competitors:

Agent	Mechanism	Indications	Resistance Rates (2-year data)	Advantages	Limitations
Lamivudine (Epivir-HBV)	Nucleoside analog	HBV monotherapy	~70%	Established safety	High resistance (YMDD mutations)
Tenofovir Disoproxil Fumarate (TDF)	Nucleotidyl analog	HBV, HIV	<20%	Lower resistance	Renal & bone toxicity risk
Entecavir	Guanosine nucleoside analog	HBV	~20%	Higher potency	Cost
Emtricitabine	Cytidine analog	HBV, HIV	Similar to lamivudine	Combination use	Resistance similar to lamivudine

Market Trends & Drivers

• Generic Penetration: Growing generic competition for lamivudine has depressed prices, impacting revenue streams for innovator companies.
• Resistance Management: Increased use of tenofovir and entecavir due to lower resistance profiles reduces lamivudine's market share.
• Combination Therapy Trends: Expansion of fixed-dose combinations (FDCs) with more potent agents diminishes lamivudine's standalone utility.
• Global Burden of HBV: Estimated 296 million people living with chronic HBV (WHO, 2021), ensuring continuous demand, especially in high-endemic regions.

Market Projections (2023-2030)

Scenario	Market Size (2022)	CAGR (2023-2030)	Notes
Conservative (Maintenance)	~$2.4 billion	~2%	Limited expansion, resistance limits growth in high-income markets
Moderate (Enhanced Access & Resistance Management)	~$2.8 billion	~4%	Increased use in resource-limited settings with generics growing
Aggressive (New Indications/Combinations)	~$3.2 billion	~6%	Potential if new formulations or approvals emerge

Source: Industry analysis reports by GlobalData (2022), evaluate the impact of generics, resistance, and guidelines.

Strategic Outlook and Future Projections

Short to Medium Term (2023-2025)

• Resistance challenges limit Epivir-HBV’s use as monotherapy; however, niche markets persist.
• Incremental growth driven by expanding indications in pediatric populations and co-infections.
• No significant clinical pipeline innovations targeting lamivudine, but combination therapies are evolving.

Long Term (2026-2030)

• Shift towards newer agents with superior resistance profiles (e.g., tenofovir alafenamide, tenofovir disoproxil fumarate).
• Persistence of lamivudine's role in resource-constrained regions, sustaining demand.
• Potential for drug repurposing or reformulation to mitigate resistance issues, especially in combination therapies.

Comparison with Emerging Therapies

New Agents	Mechanism	Clinical Status	Resistance Profile	Market Positioning
Tenofovir Alafenamide (TAF)	Nucleoside analog	Approved	Very low	Replacing TDF in many regimens
Vebatovir	HBV core inhibitor	Phase III	Expected low resistance	Potential competitor in future
RNA Interference Agents	Silences HBV RNA	Early-phase	TBD	Promising but still experimental

Conclusions and Recommendations

• Clinical Trials: Focus on combination studies and resistance mitigation to extend Epivir-HBV's utility.
• Market Positioning: Emphasize role in resource-limited settings where generic lamivudine remains a primary option.
• Investment Outlook: Marginal growth expected; market share will likely decline relative to newer agents, except in specific niches.
• Regulatory Strategy: Maintain compliance and monitor resistance trends to adapt labeling and usage guidelines.

Key Takeaways

• Limited Innovation: No recent major clinical advances or reformulations for Epivir-HBV; its role is increasingly phased out by newer, more potent agents.
• Market Dynamics: Dominated by generics, resistance issues, and competition from tenofovir and entecavir.
• Global Demand: Continues in high-burden regions; significant in pediatric and co-infection populations.
• Future Trends: Growth constrained unless new combinations or indications emerge; resistance management remains critical.
• Competitive Position: Best utilized in resource-limited settings; strategic marketing should target these markets.

FAQs

1. What is the current clinical status of Epivir-HBV?
   Epivir-HBV remains approved for HBV treatment, with ongoing clinical studies primarily evaluating combination therapies and resistance management.

2. How does Epivir-HBV compare to newer agents like tenofovir or entecavir?
   It has higher resistance rates and less potency but remains a cost-effective option in certain markets, especially where newer drugs are unavailable or unaffordable.

3. What are the major challenges facing Epivir-HBV market sustainability?
   Resistance development, competition from generics, and the advent of more effective, resistance-averse therapies limit its long-term prospects.

4. Are there any new formulations or indications under development for Epivir-HBV?
   No substantial new formulations or indications are in late-stage development; focus is predominantly on combination therapies and resistance studies.

5. What is the outlook for Epivir-HBV in resource-limited settings?
   It remains a mainstay due to affordability and existing infrastructure, with expected steady demand unless replaced by generics or better alternatives.

---

References

1. World Health Organization. (2021). Global hepatitis report 2021.
2. GlobalData. (2022). Hepatitis B market analysis and forecasts.
3. US Food and Drug Administration. (2021). Epivir-HBV (lamivudine) label updates.
4. ClinicalTrials.gov. (Accessed 2023). Summary of recent clinical trials involving lamivudine.